1st Jun 2015 08:27
LONDON (Alliance News) - Rex Bionics PLC on Monday said the first patient has been treated under the RAPPER II clinical trial, with the patient able to mobilise the REX Robot technology in less than four minutes before completing a prescribed set of exercises.
RAPPER II is a clinical trial being undertaken to determine the time taken for a wheelchair user to mobilise in a REX-powered wheelchair. All those taking part in the study are wheelchair users with a spinal cord injury.
During Robot-Assisted Physiotherapy, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises designed by specialist physiotherapists.
"This is an important milestone for REX and I'd like to thank all the people on the team who have helped to get the trial started; and thank the trial volunteers for their role in helping us to develop the technology for the benefit of current and future wheelchair users," said Crispin Simon, chief executive of Rex Bionics.
Shares in Rex Bionics were untraded Monday, having last traded at 62.80 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
RXB.L